This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Destiny Pharma Future Growth

Future criteria checks 0/6

Destiny Pharma's revenue and earnings are forecast to decline at 171.4% and 15.5% per annum respectively while EPS is expected to decline by 13.6% per annum.

Key information

-15.5%

Earnings growth rate

-13.6%

EPS growth rate

Biotechs earnings growth37.4%
Revenue growth rate-171.4%
Future return on equityn/a
Analyst coverage

Low

Last updated15 Jul 2024

Recent future growth updates

Recent updates

We're Hopeful That Destiny Pharma (LON:DEST) Will Use Its Cash Wisely

Jan 12
We're Hopeful That Destiny Pharma (LON:DEST) Will Use Its Cash Wisely

Destiny Pharma (LON:DEST) Is In A Good Position To Deliver On Growth Plans

Sep 26
Destiny Pharma (LON:DEST) Is In A Good Position To Deliver On Growth Plans

We Think Destiny Pharma (LON:DEST) Needs To Drive Business Growth Carefully

May 26
We Think Destiny Pharma (LON:DEST) Needs To Drive Business Growth Carefully

Companies Like Destiny Pharma (LON:DEST) Are In A Position To Invest In Growth

Feb 01
Companies Like Destiny Pharma (LON:DEST) Are In A Position To Invest In Growth

Will Destiny Pharma (LON:DEST) Spend Its Cash Wisely?

Aug 05
Will Destiny Pharma (LON:DEST) Spend Its Cash Wisely?

Is Destiny Pharma (LON:DEST) In A Good Position To Invest In Growth?

Apr 16
Is Destiny Pharma (LON:DEST) In A Good Position To Invest In Growth?

What Type Of Shareholders Make Up Destiny Pharma plc's (LON:DEST) Share Registry?

Feb 11
What Type Of Shareholders Make Up Destiny Pharma plc's (LON:DEST) Share Registry?

We're Hopeful That Destiny Pharma (LON:DEST) Will Use Its Cash Wisely

Nov 30
We're Hopeful That Destiny Pharma (LON:DEST) Will Use Its Cash Wisely

Earnings and Revenue Growth Forecasts

AIM:DEST - Analysts future estimates and past financials data (GBP Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2025N/A-8N/AN/A1
12/31/2024N/A-6-6-52
12/31/20231-6-6-5N/A
9/30/20231-6-5-5N/A
6/30/20231-6-5-5N/A
3/31/20231-6-6-6N/A
12/31/20220-7-6-6N/A
9/30/20220-6-5-5N/A
6/30/20220-6-5-5N/A
3/31/20220-6-5-5N/A
12/31/20210-5-5-5N/A
9/30/20210-5-7-6N/A
6/30/20210-5-9-6N/A
3/31/20210-5-8-6N/A
12/31/20200-5-8-5N/A
9/30/20200-5-6-5N/A
6/30/20200-5-4-4N/A
3/31/20200-5-4-4N/A
12/31/20190-5-5-5N/A
9/30/20190-5-5-5N/A
6/30/2019N/A-5-6-6N/A
3/31/2019N/A-5-5-5N/A
12/31/2018N/A-5-5-5N/A
9/30/2018N/A-5-4-4N/A
6/30/2018N/A-4-3-3N/A
3/31/2018N/A-4-3-3N/A
12/31/2017N/A-3-2-2N/A
9/30/2017N/A-2N/A-2N/A
6/30/2017N/A-2N/A-1N/A
3/31/2017N/A-1N/A-1N/A
12/31/2016N/A-1N/A-1N/A
12/31/2015N/A-1N/A-1N/A
12/31/2014N/A-2N/A-2N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: DEST is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: DEST is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: DEST is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: DEST is forecast to have no revenue next year.

High Growth Revenue: DEST is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if DEST's Return on Equity is forecast to be high in 3 years time


Discover growth companies